Our proprietary technology stack combines AI-powered discovery with advanced delivery systems to unlock the full potential of psychedelic medicine.
Explore Our PlatformOur proprietary AI platform accelerates drug discovery by running virtual experiments before expensive laboratory work.
Virtual screening reduces experimental costs by 80%+
Accelerate timeline from target to candidate
Structure-based drug design for precision targeting
Discovery Pipeline
Target Identification
AI-guided validation
Virtual Screening
10,000+ compounds analyzed
Lead Optimization
Non-hallucinogenic analogs
Preclinical Studies
Efficacy & safety validation
Our lean operating model and strategic partnerships deliver maximum impact with minimal burn.
4
Federal Grants Secured
3:1
Capital Leverage Ratio
0
Institutional Burn Rate
Distributed team structure eliminates overhead while maintaining world-class expertise across pharmaceutical development, AI research, and regulatory affairs.
Four federal grants validate our technology platform and scientific approach while reducing equity dilution and maintaining runway for critical development milestones.
Comprehensive intellectual property protection covering every critical component of our platform technology.
5
Discovery IP
6
Therapeutic IP
4
Delivery IP
4
Manufacturing IP
2
Commercial IP
200–1000x Manufacturing Arbitrage
Cost advantage through scalable synthesis
Non-Hallucinogenic Compounds
Breakthrough therapeutic differentiation
Integrated Platform
End-to-end from discovery to commercial
$9B+
Total Market
Fibromyalgia
Chronic Pain
SCI
Spinal Cord Injury
TNF-Alpha Inhibition
Anti-inflammatory Applications
Precise dosing over extended periods
Extended shelf life and potency
Better absorption and efficacy
Our proprietary delivery platforms solve key challenges in psychedelic therapeutics, enabling safer, more effective, and more consistent patient experiences.
From nanoparticle encapsulation to mucosal delivery systems, we're developing the pharmaceutical infrastructure needed to bring psychedelic medicine to mainstream healthcare.
Real innovation extends beyond discovery — solving difficult industry problems related to synthesis, production, and scalability.
Infrastructure-Led Development
As interest in neurotherapeutics and psychedelic-related science grows, real innovation increasingly includes improving manufacturability, reducing production barriers, building reproducible systems, and creating scalable infrastructure that can support future development.
Research continues to explore ibogaine-related science in addiction and neuropsychiatric disorders. However, the broader industry remains constrained by limited supply, non-scalable production, complex synthesis pathways, and reproducibility challenges.
Huxley Health is advancing what it believes is one of a very limited number of synthesis and manufacturing-focused patent initiatives globally targeting ibogaine at scale — representing an extended internal R&D effort to address these critical infrastructure gaps.
Innovation that addresses real-world manufacturing and supply challenges.
Building cost-efficient production capabilities as a competitive differentiator.
Creating foundational systems that support platform scalability.
Defensible intellectual property in emerging therapeutic categories.
"Huxley believes that scalable manufacturing and supply control may become defining advantages in the next phase of neurotherapeutic innovation."
Infrastructure as Competitive Moat